Investigational Cell Therapy Bemdaneprocel Shows Sustained Safety and Promising Motor Improvements at 36 Months in Parkinson’s Disease Trial – Patient Worthy

Investigational Cell Therapy Bemdaneprocel Shows Sustained Safety and Promising Motor Improvements at 36 Months in Parkinson’s Disease Trial – Patient Worthy

Bayer AG and its subsidiary BlueRock Therapeutics LP have announced encouraging 36-month follow-up data from the Phase I exPDite clinical trial of bemdaneprocel (BRT-DA01), an investigational cell therapy aimed at treating Parkinson’s disease (PD). The findings were presented at the International Congress of Parkinson’s Disease and Movement Disorders®. Bemdaneprocel is designed to replace dopamine-producing neurons […]